Posted on 2/15/19
Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown in Asia
LAWRENCE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy . . .
Posted on 2/14/19
Vor Biopharma Completes $42 Million Series A
Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies
Posted on 2/14/19
Agios Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare . . .
Posted on 2/14/19
EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
WATERTOWN, Mass., Feb. 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced . . .
Posted on 2/14/19
NeuroCycle Therapeutics Awarded NIH SBIR Grant to Study Next-Generation Treatment of Dravet Syndrome
NeuroCycle Therapeutics, Inc. (NCT) announced today that is has been awarded a $0.5M Small Business Innovation Research grant from the National institute of Neurological Disorders and . . .
Posted on 2/13/19
Healthworks Fitness Rebrands
Healthworks Fitness, Boston’s premier fitness clubs for women, is working with Fuseideas to refresh its image and brand, according to Healthworks Director of Marketing and Brand . . .
Posted on 2/13/19
Semafone Integrates With InstaMed
HIMSS -- Semafone, the leading provider of data security and compliance solutions for call and contact centers, today announced at HIMSS 2019, a partnership with InstaMed, . . .
Posted on 2/13/19
Buoy Health Strategic Partnerships Expand Digital Corporate Benefits Program Options
BOSTON--(BUSINESS WIRE)--Buoy Health (www.buoyhealth.com), a health technology company that develops AI-powered digital health solutions that empower people to effectively manage their own health and health care . . .
Posted on 2/12/19
Genocea Announces Private Placement Financing of Up to $39 Million
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered . . .
Posted on 2/12/19
Aetna Foundation, American Public Health Association and the National Association of Counties Unveil Winners of National Health Challenge
As part of an ongoing commitment to supporting community health and wellness, the Aetna Foundation today announced the two grand prize winners of the Healthiest Cities . . .
Posted on 2/12/19
Netsmart and American Well Partner
Netsmart, a provider of electronic health records (EHRs), solutions and services to more than 25,000 behavioral health, social services and post-acute organizations and American Well®, a . . .
Posted on 2/12/19
Decibel Therapeutics Selects 4G Clinical as Preferred IxRS/RTSM Provider
4G Clinical today announced a partnership with Decibel Therapeutics to enable complex trial designs for the development of novel therapies for hearing and balance disorders. As . . .
Posted on 2/12/19
Biogen 2019 Outlook
SummaryQ4 2018 results included 7% y/y revenue growth and 33% EPS growth.2019 outlook more about trial results than drug approvals or revenue growth.Effects of the Tecfidera . . .
Posted on 2/12/19
Acer Therapeutics: Multiple Aces Up Its Sleeve
SummaryAcer announced on December 26, 2018 that the FDA had accepted Acer's NDA for EDSIVO for review for the treatment of vEDS.The FDA also granted priority . . .
Posted on 2/11/19
BioDirection Receives Breakthrough Device Designation from FDA for Tbit System
BioDirection, Inc., a privately held medical device company developing cutting-edge and rapid point-of-care products for the objective diagnosis and management of concussion and other acquired traumatic . . .
Posted on 2/11/19
Cognex Could Make a Big Move When It Reports Earnings
Even as investors were prepared for muted financial results from Cognex (NASDAQ:CGNX)last quarter, they were still hoping for the best. It turned out that the quarter . . .
Posted on 2/11/19
Here's Why Sage Therapeutics Gained 48.9% in January
What happenedAfter sliding 41.8% in 2018, shares of Sage Therapeutics (NASDAQ:SAGE) jumped nearly 49% last month, according to data from S&P Global Market Intelligence. The sudden . . .
Posted on 2/10/19
Myomo Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, . . .
Posted on 2/8/19
UnitedHealthcare Confronts the Opioid Epidemic by Introducing Oral Health Programs and Policies
UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, has introduced oral health strategies to confront the opioid epidemic, building on a companywide approach to address the epidemic . . .
Posted on 2/8/19
Pulmatrix Announces $2.5 Million Registered Direct Offering Priced At-the-Market
Pulmatrix, Inc. (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,706,484 . . .
Posted on 2/8/19
ImmunoGen Reports Recent Progress and 2018 Operating Results
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress and . . .
Posted on 2/8/19
Vertex: Shareholders Might Have Reason To Breathe More Easily
SummaryVertex Pharmaceuticals has announced positive efficacy and tolerability results for the first of its two 3-drug candidates for cystic fibrosis.I expect FDA approval of whichever combo . . .
Posted on 2/8/19
Vertex Pharmaceuticals: New Drug, Same Great Growth Story
Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing its domination in cystic fibrosis, increasing the number of patients it's treating to about 18,000. And it's looking to grow that . . .
Posted on 2/8/19
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February . . .
Posted on 2/8/19
Seres Therapeutics Announces Corporate Changes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced certain corporate changes to focus resources on its highest priority, clinical-stage microbiome therapeutic candidates.“We believe that microbiome . . .

